Phase 2
Completed N=45
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Source: ClinicalTrials.gov NCT01402284 ↗Enrolled (actual)
45
Serious AEs
42.2%
Results posted
May 2017
Primary outcomePrimary: Number of Participants With Serious and Non-serious Adverse Events — 45 Participants
Summary
Background:
- Carfilzomib is an experimental anti-cancer drug that has not yet been approved for treating multiple myeloma. Lenalidomide is a drug that may stop tumor growth and help the immune system kill cancer cells. Dexamethasone is a drug that helps stop inflammation. It is sometimes used to treat (alone or with other drugs) certain types of cancer, especially multiple myeloma. This combination of drugs has not been tested in people with multiple myeloma. Researchers want to see whether it is safe and effective for this group.
Objectives:
- To test the effectiveness of combined carfilzomib, lenalidomide, and dexamethasone in treating multiple myeloma.
Eligibility:
- People at least 18 years of age who have multiple myeloma that has not been treated.
Design:
* Participants will be screened with a medical history and physical exam. They will also have blood and urine tests, a bone marrow sample, and molecular imaging studies.
* Participants will have eight 28-day cycles of treatment. The combined study drugs will be given as tablets and injections. Those in the study will be monitored with frequent blood tests, bone marrow samples, and molecular imaging studies. In addition to current standard measures to determine clinical responses, molecular tests will be conducted to define evidence of minimal residual disease.
* After the first four cycles of therapy, those who are eligible for a stem cell transplant will have stem cells collected and stored for use if the cancer returns.
* After stem cell collection, participants will have the second four treatment cycles.
-, If the disease has improved or is stable at the end of eight cycles, those in the study may have another 12 cycles of low-dose (maintenance) lenalidomide alone.
* Participants will have regular follow-up visits after the end of the study chemotherapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Serious and Non-serious Adverse Events |
45 | — |
| SECONDARY Overall Response Rate |
97.8 | — |
| SECONDARY Progression Free Survival (PFS) at 48 Months |
79.2 | — |
| SECONDARY Percentage of Responders With Duration of Response (DOR) at 48 Months |
81.1 | — |
| SECONDARY Overall Survival (OS) Rate |
89.5 | — |
| SECONDARY Cluster of Differentiation 138 (CD138) + Plasma Cells Gene Expression Profiling on Pre and Post Carfilzomib Exposure Bone Marrow Samples |
— | — |
| SECONDARY Rate of Minimal Residual Disease (MRD) by Flow Cytometry |
44.4 | — |
| SECONDARY Complete Response (CR) and Minimal Residual Disease Neg (MRDneg) CR Rates at Treatment Intervals With Carfilzomib, Lenalidomide & Dexamethasone (CRd) in New Multiple Myeloma Patients After 8 Cycles of Induction, 1 Year Maintenance, and 2 Years Maintenance |
46.7; 44.4; 20; 89; 97.8; 46.7 | — |
Eligibility Criteria
- INCLUSION CRITERIA:
- Newly diagnosed patients with histologically confirmed multiple myeloma (MM) based on the following criteria:
- Clonal plasma cells in the bone marrow
- Measurable disease within the past 4 weeks defined by any one of the following:
- Serum monoclonal protein greater than or equal to 1.0 g/dL
- Urine monoclonal protein greater than 200 mg/24 hour
- Serum immunoglobulin free light chain greater than 10 mg/dL AND abnormal kappa/lambda ratio
- Evidence of underlying end organ damage attributed to underlying plasma cell proliferative disorder meeting at least one of the following:
- Hypercalcemia: serum calcium greater than or equal to 2.65 mmol/L
- Renal Insufficiency: serum creatinine greater than 2.0 mg/dL
- Anemia: hemoglobin value less than10 g/dL or 2 g/dL less than normal reference
- Bone disease: lytic lesions, severe osteopenia or pathological fractures
- Creatinine Clearance (CrCl) greater than or equal to 60 ml/min. CrCl will be calculated by Cockcroft-Gault method. CrCl (calculated) = (140 Age) x Mass (in kilograms) x [0.85 if Female] 72 times Serum Creatinine (in mg/dL). If calculated CrCl based on Cockcroft-Gault method is <60 mL/min, patient will have a 24 hr urine collection to measure CrCl. The measured CrCl must be also greater than or equal to 60 ml/min.
- Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of carfilzomib in combination with lenalidomide in patients less than18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Absolute neutrophil count (ANC) greater than or equal to 1.0 K/uL, hemoglobin greater than or equal to 8 g/dL (transfusions are permissible), and platelet count greater than or equal to 75 K/uL
- Adequate hepatic function, with bilirubin less than 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3.0 times ULN.
- All study participants must be able to tolerate one of the following thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin (coumadin).
- All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist .
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 10-14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. Females of child bearing potential (FCBP) must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
- Subjects must be able to give informed consent
EXCLUSION CRITERIA
- Prior or concurrent systemic treatment for MM.
- Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with corticosteroids is permitted.
- Bisphosphonates are permitted.
- Treatment with corticosteroids for indications other than MM is permitted.
- Radiotherapy is permitted.
- Treatment for smoldering myeloma is permitted.
- Plasma cell leukemia
- Pregnant or lactating females. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with carfilzomib in combination with lenalidomide, breastfeeding should be discontinued if the mother is treated with carfilzomib and lenalidomide. These potential risks may also apply to other agents used in this study.
- Uncontrolled hypertension or diabetes
- Active hepatitis B or C infection
- Has sign
Data sourced from ClinicalTrials.gov (NCT01402284). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.